Discovery and SAR of thiazolidine-2,4-dione analogues as insulin-like growth factor-1 receptor (IGF-IR) inhibitors via hierarchical virtual screening

Journal of Medicinal Chemistry

Volumn 53, Issue 6, 2010, Pages 2661-2665

  Liu, Xiaofeng ^a,b   Xie, Hua ^a   Luo, Cheng ^a   Tong, Linjiang ^a   Wang, Yi ^a   Peng, Ting ^a   Ding, Jian ^a   Jiang, Hualiang ^a,b   Li, Honglin ^b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 (FURAN 2 YLMETHYLENE)THIAZOLIDINE 2,4 DIONE; 5 BENZYLIDENETHIAZOLIDINE 2,4 DIONE; ANTINEOPLASTIC AGENT; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG BINDING; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

BINDING, COMPETITIVE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DISCOVERY; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, IGF TYPE 1; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 77949859256     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901798e     Document Type: Article

References (15)

1. Randhawa, R.; Cohen, P. The role of the insulin-like growth factor system in prenatal growth. Mol. Genet. Metab. 2005, 86, 84-90.
2. Blakesley, V. A.; Scrimgeour, A.; Esposito, D.; Le Roith, D. Signaling via the insulin-like growth factor-I receptor: Does it differ from insulin receptor signaling? Cytokine Growth Factor Rev. 1996, 7, 153-159.
3. Khandwala, H. M.; McCutcheon, I. E.; Flyvbjerg, A.; Friend, K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 2000, 21, 215-244.
4. Baserga, R.; Peruzzi, F.; Reiss, K. The IGF-I receptor in cancer biology. Int. J. Cancer 2003,107, 873-877.
5. Bohula, E. A.; Playford, M. P.; Macaulay, V. M. Targeting the type 1 insulin-like growth factor receptor as anti-cancer treatment. AntiCancer Drugs 2003,14, 669-682.
6. Wittman, M.; Carboni, J.; Attar, F.; Balasubramanian, B.; Balimane, P.; Brassil, P.; Beaulieu, F.; Chang, C.; Clarke, W.; Dell, J.; Eummer, J.; Frennesson, D.; Gottardis, M.; Greer, A.; Hansel, S.; Hurlburt, W.; Jacobson, B.; Krishnananthan, S.; Lee, F. Y.; Li, A.; Lin, T.-A.; Liu, P.; Ouellet, C.; Sang, X.; Saulnier, M. G.; Stoffan, K.; Sun, Y.; Velaparthi, U.; Vyas, D.; Wong, H.; Yang, Z.; Zimmermann, K.; Zoeckler, M.; Vyas, D. Discovery of a (1Hbenzimidazol-2-yl)-l//- pyridine-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity. J. Med. Chem. 2005, 48, 5639-5643.
7. Mayer, S. C.; Banker, A. L.; Boschelli, F.; Di, L.; Johnson, M.; Kenny, C. H.; Krishnamurthy, G.; Kutterer, K.; Moy, F.; Petusky, S.; Ravi, M.; Tkach, D.; Tsou, H. R.; Xu, W. Lead identification to generate isoquinolinedione inhibitors of insulin-like growth factor receptor (IGF-IR) for potential use in cancer treatment. Bioorg. Med. Chem. Lett. 2008, 18, 3641-3645.
8. Miller, L. M.; Mayer, S. C.; Berger, D. M.; Boschelli, D. H.; Boschelli, F.; Di, L.; Du, X.; Dutia, M.; Floyd, M. B.; Johnson, M.; Kenny, C. H.; Krishnamurthy, G.; Moy, F.; Petusky, S.; Tkach, D.; Torres, N.; Wu, B.; Xu, W. Lead identification to generate 3-cyanoquinoline inhibitors of insulin-like growth factor receptor (IGF-IR) for potential use in cancer treatment. Bioorg. Med. Chem. Lett. 2009, 19, 62-66.
9. Hubbard, R. D.; Bamaung, N. Y.; Palazzo, F.; Zhang, Q.; Kovar, P.; Osterling, D. J.; Hu, X.; Julie; Wilsbascher, J. L.; Johnson, E. F.; Bouska, K.; Wang, J.; Bell, R. L.; Davidsen, S. K.; Sheppard, G. S. Pyrazolo[3,4-d] pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR). Bioorg. Med. Chem. Lett. 2007, 17, 5406-5409.
10. Heidi, S. C. Thiazolidinediones in diabetes: current status and future outlook. Curr. Opin. Invest. Drugs 2003, 4, 406-411.
11. Camps, M.; Ruckle, T.; Ji, H.; Ardissone, V.; Rintelen, F.; Shaw, J.; Ferrandi, C.; Chabert, C.; Gillieron, C.; Françon, B.; Martin, T.; Gretener, D.; Perrin, D.; Leroy, D.; Vitte, P. A.; Hirsch, E.; Wymann, M. P.; Crillo, R.; Schwarz, M. K.; Rommel, C. Blockade of PDKgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 2005, 11, 936-943.
12. Xia, Z.; Knaak, C.; Ma, J.; Beharry, Z. M.; Mclnnes, C.; Wang,W.; Kraft, A. S.; Smith, C. D. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J. Med. Chem. 2005, 9, 74-86.
13. Katritzky, A. R.; Tala, S. R.; Lu, H.; Vakulenko, A. V.; Chen, Q. Y.; Sivapackiam, J.; Pandya, K.; Jiang, S.; Debnath, A. K. Design, synthesis, and structure-activity relationship of a novel series of 2-aryl5-(4-oxo-3-phenethyl- 2-thioxothiazolidinylidenemethyl)furans as HIV-I entry inhibitors. J. Med. Chem. 2009, 52, 7631-7639.
14. Guobin, H.; Youme, S.; John, D.; Susan, M. F. Thiazolidinediones inhibit insulin-like growth factor-I induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. Cancer Res. 2006, 66,1873-1879.
15. Lu, Y.; Shi, T.; Wang, Y.; Yang, Y.; Yan, X.; Luo, X.; Jiang, H.; Zhu, W. Halogen bonding, a novel interaction for rational drug design? J. Med. Chem. 2009, 52, 2854-2862.